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OBJECTIVES: Several large scale surveys conducted to measure time-preferences
of people in various fields, other than those in the health outcomes, have shown
that time-preferences follow non-constant exponential discounting. In pharmaco-
economic studies, however, all outcomesmeasures including quality-adjusted life-
years (QALYs) use discrete discounting. Disability-adjusted life-years (DALYs) is an
exception that is discounted using the non-constant exponential discounting ap-
proach. The objective of this study is to review the current literature on time-
preferences specific to health outcomes and compare the differences between
QALYs obtained through discrete discounting and non-constant exponential dis-
counting approaches. METHODS: We searched PubMed and EconLit for method-
ological studies examining time-preferences specific to health outcomes. We pro-
jected gains of 0.1 QALY/person/year over 1 to 75 years in a hypothetical dataset of
1000 persons. We calculated differences in present values of QALYs obtained
through discrete discounting and non-constant exponential discounting ap-
proaches, i.e. QALYs from discrete discounting subtracted by QALYs from non-
constant exponential discounting, at discount rates of 1.5%, 3%, 5%, and 7%, from 1
to 75 years. RESULTS:We found no studies that examined discounting approaches
specific to health outcomes. The differences in present values of QALYs, at 25, 50,
and 75 years, respectively, were: 1) 0.28%, 0.55%, and 0.83%, using a 1.5% discount
rate; 2) 1.1%, 2.2%, and 3.3%, using a 3% discount rate; 3) 3%, 5.9%, and 8.7%, using
a 5% discount rate; and 4) 5.7%, 11.1%, and 16.1%, using a 7% discount rate.
CONCLUSIONS: We found no published research comparing discrete discounting
to non-constant exponential discounting approaches for QALYs. Over long time
horizons, we found small but conceptually important differences between QALYs
estimated by these approaches. Therefore, we recommend future studies to ad-
dress time-preferences specific to determine if non-constant exponential dis-
counting is relevant to health outcomes such as QALYs.
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OBJECTIVES: The Center for Medicaid and Medicare Services (CMS) has created
plan Star ratings that indicate the quality of Medicare plans. In 2012, CMS added
three pharmacy measures that focus on member medication adherence, i.e. oral
diabetes medications, hypertension medication (ACEI or ARB), and cholesterol
medication (statins). To proactively identify patients at risk for non-adherence, a
multi-variate regression prediction model was developed to create individual per-
sistency risk scores.METHODS: The predictive model is created using prescription
drug and medical claims from a large managed care database. Medicare and com-
mercially insured patients over age 55 from 2008-2010 who are new to the Star
rating medication categories are included. Patients included in the model have a
full 18 months of continuous enrollment in the health plan (6 month drug naïve
period, 12 months of follow up). The predictors are created from the 6 month pre
period and include: a) socio-economic factors; b) medical characteristics (e.g.
Charlson Comorbidity Index); and c) drug characteristics (i.e. drug cost and past
chronic drug adherence). RESULTS: Multivariable analysis of study outcomes will
be conducted using appropriate regressionmodels based on the distribution of the
measure. A logistic regressionmodel will be estimated (1 for at least 80% PDC,0
for non-compliance). Results of a logistic regressionwill be presented as odds ratios
associated with each independent variable. The parameter estimates from the
above econometric model will be retained and used to estimate the probability of
non-compliance on a new set of patients. To test the accuracy of the predictive
model, we will choose a random sample of patients new to these medications in
2011, as exhibited by the average PDC in each risk group (high, medium, low).
CONCLUSIONS: An adherence predictive model can be useful to identify patients
who may benefit from a drug adherence intervention program.
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OBJECTIVES: Korea’s Health Insurance Review and Assessment Service (HIRA) has
been in charge of formulating economic evaluation guideline and evaluating sub-
missions for reimbursement decision. The purpose of this study is to observe cur-
rent practice patterns of using decision analyticmodels in submissions considered
by HIRA.METHODS: Thirty-four dossiers were submitted by industry from January
2007 until December 2009, and they were evaluated by two independent research-
ers at HIRA. The adherence to current HIRA’s recommendation was assessed.
RESULTS: Out of 34 submissions, 23 applied model-based evaluations, and more
than half (14) submissionswere based onmarkovmodeling. Dynamicmodels were
not applied any of the submissions. Submissions frequently omitted the justifica-
tion of the assumptions, definition of markov states or cycle length. Parameter
search /selection criteria were rarely provided, and usually extrapolated in favor of
the applicants. Transparencywas lacking especiallymodelswith long timehorizon
and multiple assumptions, and submitted models were rarely validated.
CONCLUSIONS:Decision analytic models are frequently applied in economic eval-
uation dossiers, yet the quality of provided models varied greatly. Revised HIRA’s
guideline could specify the minimum standard of modeling to increase the com-
parability of submitted dossiers.
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OBJECTIVES: To define an operational modelling framework intended to help the
design of Performance-Based Risk-Sharing (PBRS) schemes. A time-to-event end-
point is used as a performance criterion. Such survival endpoints are commonly
used in clinical studies, notably in oncology where PBRS schemes are gaining
momentum. METHODS: The framework is based on an open population model
with a monthly cycle and 3-year time horizon from launch (i.e. when enrolment
into the PBRS scheme starts). Entry into the model (i.e. the progressive arrival of
new patients into the PBRS scheme) is determined by market diffusion assump-
tions and is modelled using a Logistic function. Exit from the model (i.e. patients
experiencing the event or dying from any cause) is determined by survival curves
from clinical/epidemiological studies and is modelled using a Weibull function.
The model accommodates different treatment dosing schedules and performance
levels (i.e. minimum survival times guaranteed). Multiple PBRS scenarios can be
run and compared in terms of their operational and financial implications. Addi-
tionally, the effect of potential revisions of a PBRS scheme terms and conditions
can also be examined as real-life information becomes available following scheme
implementation (i.e. Bayesian updating). RESULTS: For example, assuming 1,000
patients enrolled in a PBRS scheme, with a monthly dosing schedule and given
diffusion (Logistic 5.0; 0.4) and survival (Weibull 0.7; k27.0) assumptions,
the model predicts that 1937 (6970), 4050 (7861) and 9282 (4420) doses will be given
to non-responding (responding) patients with 12, 18 and 24 months minimum
survival time guaranteed scenarios, respectively. CONCLUSIONS: This framework
provides both payer and manufacturer with valuable insight into the operational
and financial dimensions of the potential PBRS schemes they may contemplate as
they negotiate patient access conditions. Both parties can better anticipate the
implications of the schemes and better plan resources, logistics and financial ar-
rangements accordingly.
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OBJECTIVES: To evaluate a web-based software program which incorporates
Markov Chain Monte Carlo (MCMC) analysis to compare the cost-effectiveness of
any two treatments, allowing modifiable inputs of key variables. METHODS: A
web-based software program was developed, which incorporates Markov Chain
Monte Carlo (MCMC) analysis to compare the cost-effectiveness of any two treat-
ments. The online software program was based on calculation methods described
in “Decision Making in Health and Medicine” textbook from Hunink et al. The
MCMC web-based program computes and graphically displays the results, using
JavaScript algorithms and is available as freeware at www.healthstrategy.com.We
compared the online resultswith analyses usingDecisionMaker software available
from UMDNJ.edu. The variable inputs that can be modified in the web-based ap-
plication include: state transition probabilities, number of patients, number of
cycles, cost per state, and utility per state. RESULTS: The web-based tool creates
plots of incremental costs versus incremental utilities, in cost-effectiveness quad-
rants; and if death is the absorbing state, also graphs life expectancy curves for two
treatment comparisons. As an example of the similarity of findings, when consid-
ering three transition states per treatment, the online software versus the Decision
Maker model results were as follows: treatment cost (means: $1417 vs. $1300 and
standard deviations: 1706 vs. 1604); treatment effectiveness (means: 7.6 vs. 7.8 and
standard deviations: 7.2 vs. 7.0). CONCLUSIONS:With this online MCMC program,
the user can input their own therapy parameters, and then generate key means
and standard deviations, incremental costs, incremental utilities, life expectancy
curves, and incremental cost effectiveness ratios. MCMC has advantages over
Markov cohort analyses because means and standard deviations can be generated
from theMCMC calculations. This web-based application has potential benefit as a
basic educational tool for students and health professionals interested in exploring
these analytical approaches.
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OBJECTIVES:Markov models are often used in Health Economics to represent dis-
ease progression in Cost-Utilitymodels. The transition probabilities, however,may
be difficult to populate when the data are limited. This note applies the Markov
matrix approximation method using vector autoregression (VAR) to estimate the
transition matrix when the sample size is small.METHODS:We compare the per-
formance of the standard (count) method versus the VAR method to estimate
transition probabilities in small samples. For the count method, one counts the
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